Changeflow GovPing Pharma & Drug Safety Polymeric Delivery System Patent for Biologics
Routine Notice Added Final

Polymeric Delivery System Patent for Biologics

Favicon for changeflow.com USPTO Patent Applications - Pharma (A61K)
Published
Detected
Email

Summary

USPTO published patent application US20260096990A1 for a polymeric delivery system designed to deliver biologic therapeutics to cells. The invention covers polyplexes composed of charged polyesters and biologics, as well as self-assembled particles with block copolymers. The application was filed on December 12, 2025, by inventors Jeremy J. Harris, Scott Radzinski, Brian Ginn, Peter D. Gabriele, and Benjamin Roadarmel.

What changed

USPTO published patent application US20260096990A1 disclosing a polymeric delivery system for administering biologic therapeutics to cells. The system includes polyplexes combining charged polyester copolymers with biologics, as well as self-assembled particles featuring block copolymers. CPC classifications span drug formulations, nucleic acid delivery, and polymer chemistry.

Patent applicants and pharmaceutical companies developing biologic therapeutics should monitor this application for potential overlap with their own IP strategies. The published application does not create compliance obligations but may inform competitive landscape analysis for drug delivery technologies.

What to do next

  1. Monitor for updates

Archived snapshot

Apr 13, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

POLYMERIC DELIVERY SYSTEMS

Application US20260096990A1 Kind: A1 Apr 09, 2026

Inventors

Jeremy J. HARRIS, Scott Radzinski, Brian Ginn, Peter D. Gabriele, Benjamin Roadarmel

Abstract

A polymeric delivery system delivers a biologic to cells. In some embodiments, the polymeric delivery system includes polyplexes. Each polyplex includes at least one charged polymer and at least one biologic. The at least one charged polymer includes a polyester copolymer of a polyol and a polycarboxylic acid modified with at least one charged moiety having an opposite charge from a net charge of the at least one biologic. In other embodiments, the polymeric delivery system includes self-assembled particles including a block copolymer and a biologic associated with the block copolymer. The block copolymer includes a first block of a polyester copolymer of a polyol and a polycarboxylic acid and a second block of a second monomer or a second polymer.

CPC Classifications

A61K 9/1647 A61K 9/5026 A61K 9/5146 A61K 31/7105 A61K 31/711 A61K 47/34 B82Y 5/00 C08F 120/60 A61K 48/00

Filing Date

2025-12-12

Application No.

19418027

View original document →

Get daily alerts for USPTO Patent Applications - Pharma (A61K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 9th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260096990A1

Who this affects

Applies to
Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent filing Biologic drug delivery Polymer technology
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare Biotechnology

Get alerts for this source

We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!